Flemming Davidsen

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Adverse drug reactions and drug non-compliance as primary causes of admission to a cardiology department

Flemming Davidsen, Torben Haghfelt, L. F. Gram et al. · European Journal of Clinical Pharmacology · 1988 · 61 citations

Pharmacy, Cardiology, Pharmacology +13

The Economics of an Intensive Education Programme for Asthmatic Patients

Birthe Søndergaard, Flemming Davidsen, Bente Kirkeby et al. · PharmacoEconomics · 1992 · 49 citations

Health Professions, Health Education, Health Economics +7